Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Terry D. who wrote (3179)	7/22/1999 10:59:00 AM
From: Terry D.	Respond to of 3702

Techniclone's Cotara Trial and Drug Distribution Data to be Presented at Prestigious Congress of Neurological Surgeons Meeting Phase I Abstract and Select Phase II Data to be Reviewed During Annual Conference As Well As Abstract on The Regional Distribution of Cotara(TM) TUSTIN, Calif.--(BUSINESS WIRE)--July 22, 1999-- Techniclone Corporation (NASDAQ:TCLN - news) announced today that Dr. Sunil Patel (Medical University of South Carolina), principal investigator for the Company's Cotara(TM) clinical trials for the treatment of malignant glioma, has been accepted to present two abstracts detailing select results from the study during the prestigious Congress of Neurological Surgeons Meeting being held October 30th - November 4th in Boston, MA. One of the abstracts to be presented by Dr. Patel will outline results from the 12 patient Phase I study recently conducted at the Medical University of South Carolina, as well as limited data from the Company's ongoing Phase II trial for the treatment of malignant glioma, the most deadly form of brain cancer. A second abstract will present new data generated from the Phase I Cotara(TM) studies regarding drug distribution of a radiolabeled antibody through the use of a low-pressure intra-tumoral catheter as measured by innovative scanning techniques. Cotara(TM) is an innovative therapy for the treatment of various forms of solid tumor cancer and is currently in a Phase II clinical study involving 60 malignant glioma brain cancer patients, as well as a Phase I/II trial presently underway for the treatment of prostate, pancreatic and liver cancers. Larry O. Bymaster, President and CEO of Techniclone, stated, ''We are delighted to have this opportunity to participate in what is certainly one of the year's most prominent gatherings of neurological surgeons, and to present the trial results for Cotara(TM), as well as an abstract on the state-of-the-art delivery method being employed during these trials. We look forward to sharing our progress to-date towards the treatment of this devastating disease with many of the world's most prominent neurosurgeons. Each year, tens of thousands of individuals are diagnosed with various forms of solid tumor brain cancer, the majority of which fail to survive more than 9-12 months. While in the past, treatment options have been limited and for the most part ineffective, we believe that the Phase I Cotara(TM) results show true promise and we are anxiously following the ongoing Phase II study in hopes of someday providing relief to these patients.'' Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer primarily based on its ''collateral targeting technologies''. These technologies therapeutically target cell structure and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. In addition to Cotara(TM), the Company has two other collateral targeting agents: Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA), both of which are in pre-clinical stages of development. VEAs are monoclonal anitbodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutics agents versus normal tissues, while VTAs are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTA's also can deliver a wide variety of therapeutic agents to a solid tumor, including therapeutic agents, biologic agents, toxins and radioisotopes. The Company also has a direct tumor targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma which was recently license to Schering AG, Germany, which is now responsible for all existing and future Oncolym® clinical trial programs as well as marketing. Additional information on the Company and its products and its products can be found at www.techniclone.com.